Related Experiment Video
Updated: Apr 11, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Biologics in vasculitides: Where do we stand, where do we go from now?
Giulia Pazzola1, Francesco Muratore1, Nicolò Pipitone1
1Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
Abstract:
Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.
More Related Videos
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids